Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Altering cellular reducing potential changes 64Cu-ATSM signal with or without hypoxia.

Floberg JM, Wang L, Bandara N, Rashmi R, Mpoy C, Garbow JR, Rogers BE, Patti GJ, Schwarz JK.

J Nucl Med. 2019 Oct 4. pii: jnumed.119.230805. doi: 10.2967/jnumed.119.230805. [Epub ahead of print]

PMID:
31586008
2.

CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia.

Muz B, Bandara N, Mpoy C, Sun J, Alhallak K, Azab F, Rogers BE, Azab AK.

Cancer Biol Ther. 2019 Oct 1:1-9. doi: 10.1080/15384047.2019.1665405. [Epub ahead of print]

PMID:
31571524
3.

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

PMID:
31270275
4.

PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.

Kapoor V, Singh AK, Rogers BE, Thotala D, Hallahan DE.

J Control Release. 2019 Mar 28;298:194-201. doi: 10.1016/j.jconrel.2019.02.008. Epub 2019 Feb 11.

PMID:
30763622
5.

Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution.

Diebolder P, Vazquez-Pufleau M, Bandara N, Mpoy C, Raliya R, Thimsen E, Biswas P, Rogers BE.

Int J Nanomedicine. 2018 Nov 12;13:7375-7393. doi: 10.2147/IJN.S177350. eCollection 2018.

6.

Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.

Zhou D, Xu J, Mpoy C, Chu W, Kim SH, Li H, Rogers BE, Katzenellenbogen JA.

Nucl Med Biol. 2018 Nov;66:26-31. doi: 10.1016/j.nucmedbio.2018.08.003. Epub 2018 Aug 24.

PMID:
30195072
7.

Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.

Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ.

Nucl Med Biol. 2018 Jul - Aug;62-63:71-77. doi: 10.1016/j.nucmedbio.2018.06.001. Epub 2018 Jun 8.

8.

Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.

Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE.

Bioconjug Chem. 2018 Jul 18;29(7):2448-2454. doi: 10.1021/acs.bioconjchem.8b00341. Epub 2018 Jul 2.

PMID:
29927587
9.

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA.

Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13.

10.

Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer's Disease.

Bandara N, Sharma AK, Krieger S, Schultz JW, Han BH, Rogers BE, Mirica LM.

J Am Chem Soc. 2017 Sep 13;139(36):12550-12558. doi: 10.1021/jacs.7b05937. Epub 2017 Aug 29.

11.

Copper import in Escherichia coli by the yersiniabactin metallophore system.

Koh EI, Robinson AE, Bandara N, Rogers BE, Henderson JP.

Nat Chem Biol. 2017 Sep;13(9):1016-1021. doi: 10.1038/nchembio.2441. Epub 2017 Jul 24.

12.

Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers.

Kapoor V, Dadey DY, Nguyen K, Wildman SA, Hoye K, Khudanyan A, Bandara N, Rogers BE, Thotala D, Hallahan DE.

J Nucl Med. 2016 Dec;57(12):1991-1997. Epub 2016 Jul 21.

13.

Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.

Richter S, Wuest M, Bergman CN, Krieger S, Rogers BE, Wuest F.

Mol Pharm. 2016 Apr 4;13(4):1347-57. doi: 10.1021/acs.molpharmaceut.5b00970. Epub 2016 Mar 23.

PMID:
26973098
14.

Transferrin conjugates of triazacyclononane-based bifunctional NE3TA chelates for PET imaging: Synthesis, Cu-64 radiolabeling, and in vitro and in vivo evaluation.

Kang CS, Wu N, Chen Y, Sun X, Bandara N, Liu D, Lewis MR, Rogers BE, Chong HS.

J Inorg Biochem. 2016 Jan;154:60-6. doi: 10.1016/j.jinorgbio.2015.10.012. Epub 2015 Oct 30.

15.

Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein.

Lears KA, Parry JJ, Andrews R, Nguyen K, Wadas TJ, Rogers BE.

Cancer Gene Ther. 2015 Mar;22(4):215-21. doi: 10.1038/cgt.2015.14. Epub 2015 Apr 3.

16.

Rerouting the metabolic pathway of (18)F-labeled peptides: the influence of prosthetic groups.

Richter S, Wuest M, Bergman CN, Way JD, Krieger S, Rogers BE, Wuest F.

Bioconjug Chem. 2015 Feb 18;26(2):201-12. doi: 10.1021/bc500599m. Epub 2015 Jan 26.

PMID:
25572982
17.

Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase.

Chapman AM, Rogers BE, McNaughton BR.

Biochemistry. 2014 Nov 11;53(44):6857-9. doi: 10.1021/bi5012354. Epub 2014 Oct 29.

18.

Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene.

Dmitriev IP, Kashentseva EA, Kim KH, Matthews QL, Krieger SS, Parry JJ, Nguyen KN, Akers WJ, Achilefu S, Rogers BE, Alvarez RD, Curiel DT.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00024.

PMID:
25249483
19.

Cross-inhibition of NMBR and GRPR signaling maintains normal histaminergic itch transmission.

Zhao ZQ, Wan L, Liu XY, Huo FQ, Li H, Barry DM, Krieger S, Kim S, Liu ZC, Xu J, Rogers BE, Li YQ, Chen ZF.

J Neurosci. 2014 Sep 10;34(37):12402-14. doi: 10.1523/JNEUROSCI.1709-14.2014.

20.

Construction and radiolabeling of adenovirus variants that incorporate human metallothionein into protein IX for analysis of biodistribution.

Liu L, Rogers BE, Aladyshkina N, Cheng B, Lokitz SJ, Curiel DT, Mathis JM.

Mol Imaging. 2014 Sep;13(7). doi: 10.2310/7290.2014.00022.

PMID:
25060486
21.

64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies.

Cai Z, Ouyang Q, Zeng D, Nguyen KN, Modi J, Wang L, White AG, Rogers BE, Xie XQ, Anderson CJ.

J Med Chem. 2014 Jul 24;57(14):6019-29. doi: 10.1021/jm500416f. Epub 2014 Jul 11.

22.

Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.

Marquez BV, Ikotun OF, Parry JJ, Rogers BE, Meares CF, Lapi SE.

J Nucl Med. 2014 Jun;55(6):1029-34. doi: 10.2967/jnumed.113.130898. Epub 2014 Apr 14.

23.

AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.

Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW, Schwarz JK.

PLoS One. 2014 Apr 4;9(4):e92948. doi: 10.1371/journal.pone.0092948. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107846. Rader, Janet [corrected to Rader, Janet L].

24.

Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure-activity evaluation.

Li H, Zhou H, Krieger S, Parry JJ, Whittenberg JJ, Desai AV, Rogers BE, Kenis PJ, Reichert DE.

Bioconjug Chem. 2014 Apr 16;25(4):761-72. doi: 10.1021/bc500034n. Epub 2014 Apr 4.

25.

Novel hexadentate and pentadentate chelators for ⁶⁴Cu-based targeted PET imaging.

Sin I, Kang CS, Bandara N, Sun X, Zhong Y, Rogers BE, Chong HS.

Bioorg Med Chem. 2014 Apr 15;22(8):2553-62. doi: 10.1016/j.bmc.2014.02.041. Epub 2014 Mar 1.

26.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.

PMID:
23969085
27.

The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.

Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ.

J Nucl Med. 2013 Sep;54(9):1621-9. doi: 10.2967/jnumed.112.118539. Epub 2013 Jul 19.

28.

Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands.

Nanda PK, Wienhoff BE, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Rogers BE, Smith CJ.

In Vivo. 2012 Jul-Aug;26(4):583-92.

PMID:
22773572
29.

Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development.

De Silva RA, Jain S, Lears KA, Chong HS, Kang CS, Sun X, Rogers BE.

Nucl Med Biol. 2012 Nov;39(8):1099-104. doi: 10.1016/j.nucmedbio.2012.05.009. Epub 2012 Jun 27.

30.

Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.

Parry JJ, Chen R, Andrews R, Lears KA, Rogers BE.

Endocrinology. 2012 Jun;153(6):2747-55. doi: 10.1210/en.2011-1662. Epub 2012 Apr 11.

31.

In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.

Craft JM, De Silva RA, Lears KA, Andrews R, Liang K, Achilefu S, Rogers BE.

Nucl Med Biol. 2012 Jul;39(5):609-16. doi: 10.1016/j.nucmedbio.2011.12.004. Epub 2012 Jan 20.

32.

Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.

Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW.

Clin Cancer Res. 2012 Mar 1;18(5):1464-71. doi: 10.1158/1078-0432.CCR-11-2485. Epub 2012 Jan 10.

33.

Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.

Nguyen K, Parry JJ, Rogers BE, Anderson CJ.

Nucl Med Biol. 2012 Feb;39(2):187-97. doi: 10.1016/j.nucmedbio.2011.08.006. Epub 2011 Nov 4.

34.

In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.

Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.

J Nucl Med. 2011 Mar;52(3):470-7. doi: 10.2967/jnumed.110.082826. Epub 2011 Feb 14.

35.

Multimodality imaging of gene transfer with a receptor-based reporter gene.

Chen R, Parry JJ, Akers WJ, Berezin MY, El Naqa IM, Achilefu S, Edwards WB, Rogers BE.

J Nucl Med. 2010 Sep;51(9):1456-63. doi: 10.2967/jnumed.109.063586. Epub 2010 Aug 18.

36.

Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx.

Kitamura T, Fukuyo Y, Inoue M, Horikoshi NT, Shindoh M, Rogers BE, Usheva A, Horikoshi N.

Cancer Res. 2009 Oct 1;69(19):7681-8. doi: 10.1158/0008-5472.CAN-09-2133. Epub 2009 Sep 29.

37.

Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.

Geng L, Rachakonda G, Morré DJ, Morré DM, Crooks PA, Sonar VN, Roti JL, Rogers BE, Greco S, Ye F, Salleng KJ, Sasi S, Freeman ML, Sekhar KR.

FASEB J. 2009 Sep;23(9):2986-95. doi: 10.1096/fj.09-130005. Epub 2009 Apr 24.

38.

PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts.

Parry JJ, Sharma V, Andrews R, Moros EG, Piwnica-Worms D, Rogers BE.

Cancer Gene Ther. 2009 Feb;16(2):161-70. doi: 10.1038/cgt.2008.70. Epub 2008 Aug 29.

39.

Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Anderson CJ, Achilefu S.

Bioconjug Chem. 2008 Jan;19(1):192-200. Epub 2007 Nov 20.

40.

Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.

Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ.

J Nucl Med. 2007 Aug;48(8):1390-6. Epub 2007 Jul 13.

41.

In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties.

Parry JJ, Kelly TS, Andrews R, Rogers BE.

Bioconjug Chem. 2007 Jul-Aug;18(4):1110-7. Epub 2007 May 16.

PMID:
17503761
42.

Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).

Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS.

Bioconjug Chem. 2007 May-Jun;18(3):724-30. Epub 2007 Mar 23.

PMID:
17378600
43.

Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.

Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE.

Mol Imaging. 2007 Jan-Feb;6(1):56-67.

PMID:
17311765
44.

MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.

Parry JJ, Andrews R, Rogers BE.

Breast Cancer Res Treat. 2007 Jan;101(2):175-83. Epub 2006 Jul 13.

PMID:
16838112
45.

Composition and clinical use of hemodialysates.

Sam R, Vaseemuddin M, Leong WH, Rogers BE, Kjellstrand CM, Ing TS.

Hemodial Int. 2006 Jan;10(1):15-28.

PMID:
16441823
46.

MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1.

Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T.

J Nucl Med. 2005 Nov;46(11):1889-97.

47.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

48.

Experience with a small animal hyperthermia ultrasound system (SAHUS): report on 83 tumours.

Novák P, Moros EG, Parry JJ, Rogers BE, Myerson RJ, Zeug A, Locke JE, Rossin R, Straube WL, Singh AK.

Phys Med Biol. 2005 Nov 7;50(21):5127-39. Epub 2005 Oct 19.

PMID:
16237245
49.

Expression of the proto-oncogene Fos after exposure to radiofrequency radiation relevant to wireless communications.

Whitehead TD, Brownstein BH, Parry JJ, Thompson D, Cha BA, Moros EG, Rogers BE, Roti Roti JL.

Radiat Res. 2005 Oct;164(4 Pt 1):420-30.

PMID:
16187744
50.

In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.

Rogers BE, Manna DD, Safavy A.

Cancer Biother Radiopharm. 2004 Feb;19(1):25-34.

PMID:
15068608

Supplemental Content

Loading ...
Support Center